Ads
related to: multiple myeloma treatment- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Contact a Representative
For Questions and Information
About This Treatment
- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Primary and Subgroup Data
Search results
AbbVie makes oncology progress with two drug trials
Crain s Chicago Business· 1 day agoMultiple myeloma, the second-most common blood cancer, is characterized by abnormal proliferation of plasma cells, which can cause end-organ damage, AbbVie ...
GSK blood cancer drug nearly halves risk of death in late-stage trial
Reuters via AOL· 6 days agoGSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared...
AbbVie treats first subject in Phase III multiple myeloma drug trial
Clinical Trials Arena via Yahoo Finance· 2 days agoIII CERVINO clinical trial of its investigational product ABBV-383 to treat relapsed/refractory ...
CARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened...
Valley City Times Record· 4 days agoJohnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. Data from the CARTITUDE-4 study supported the recent U.S. FDA approval of CARVYKTI®, the ...
Become part of a movement to accelerate a cure for multiple myeloma!
Digital Journal· 3 days agomyeloma patients. With continued support, and efforts such as the Walk / Run in cities across the country this August – December Multiple Myeloma ...
DARZALEX® (daratumumab)-based regimens significantly improve clinical outcomes in both...
Valley City Times Record· 4 days agoThe rates of deep and sustained MRD negativity were associated with improved progression-free...
TECVAYLI® (teclistamab-cqyv) shows sustained deep and durable responses in patients with relapsed or...
Valley City Times Record· 5 days ago"With the longest follow-up of any bispecific antibody, teclistamab demonstrates continued deep and durable responses observed in patients with relapsed or refractory multiple
Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed...
Pharmaceutical Executive Magazine· 3 days agoEffective frontline therapy has the potential to modify the course of the disease, which is a key...
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
Zacks via Yahoo Finance· 2 days agoThe late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with...
Adding Isatuximab to Standard Backbone Improves Outcomes in Multiple Myeloma
MedPage Today· 4 days agoTwo trials show positive outcomes
Ads
related to: multiple myeloma treatment
